Xenetic Biosciences (NASDAQ:XBIO) will report on Q2 2022.
Why Ardelyx Shares Tanked Today
Ardelyx (NASDAQ: ARDX) shares are trading lower after the company received an FDA letter regarding its NDA for tenapanor indicating deficiencies that preclude discussion of labeling and post-marketing requirements/comments at this time.